Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.
Hasan SK, Mays AN, Ottone T, Ledda A, La Nasa G, Cattaneo C, Borlenghi E, Melillo L, Montefusco E, Cervera J, Stephen C, Satchi G, Lennard A, Libura M, Byl JA, Osheroff N, Amadori S, Felix CA, Voso MT, Sperr WR, Esteve J, Sanz MA, Grimwade D, Lo-Coco F. Hasan SK, et al. Among authors: lennard a. Blood. 2008 Oct 15;112(8):3383-90. doi: 10.1182/blood-2007-10-115600. Epub 2008 Jul 23. Blood. 2008. PMID: 18650449 Free PMC article.
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL. Talpaz M, et al. Among authors: lennard al. Blood. 2002 Mar 15;99(6):1928-37. doi: 10.1182/blood.v99.6.1928. Blood. 2002. PMID: 11877262 Free article. Clinical Trial.
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP, Lennard AL, Pallan L, Arrazi JM, Perz JB, O'Shea D, Goldman JM, Apperley JF, Craddock CF. Olavarria E, et al. Blood. 2007 Dec 15;110(13):4614-7. doi: 10.1182/blood-2007-04-082990. Epub 2007 Sep 19. Blood. 2007. PMID: 17881635 Free article. Clinical Trial.
The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control.
Proctor SJ, Lennard AL, Jackson GH, Jones GL, Lewis J, Wilkinson J, White J, Sieniawski M, McKay P, Culligan D, Lucraft HH. Proctor SJ, et al. Among authors: lennard al. Ann Oncol. 2010 Feb;21(2):426-428. doi: 10.1093/annonc/mdp527. Epub 2009 Nov 9. Ann Oncol. 2010. PMID: 19901016 Free article. Review. No abstract available.
Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial.
Stanworth SJ, Killick S, McQuilten ZK, Karakantza M, Weinkove R, Smethurst H, Pankhurst LA, Hodge RL, Hopkins V, Thomas HL, Deary AJ, Callum J, Lin Y, Wood EM, Buckstein R, Bowen D; REDDS Investigators. Stanworth SJ, et al. Br J Haematol. 2020 Apr;189(2):279-290. doi: 10.1111/bjh.16347. Epub 2020 Jan 20. Br J Haematol. 2020. PMID: 31960409 Free article. Clinical Trial.
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH. Proctor SJ, et al. Among authors: lennard al. Eur J Haematol Suppl. 2001 Jul;64:28-32. Eur J Haematol Suppl. 2001. PMID: 11486397 Clinical Trial.
105 results